Pharmacological inhibition of EGFR has shown to reduce high-fat diet-induced liver injury in mouse models of NAFLD (73, 74), suggesting that targeting EGFR signaling may prove to have therapeutic potential in human NASH. This evidence concerns the gene EGFR and metabolic dysfunction-associated steatohepatitis.